Progentos Therapeutics Raises $65M in Funding for Regenerative Therapies and Expansion

Progentos Therapeutics' Series A Funding

Key Highlights:

• Series A Funding: Closed a $65 million series A funding round led by Forbion, with participation from Alta Partners, Mission BioCapital, Longwood Fund, and Dolby Family Ventures.
• Regenerative Therapies: Developing first-in-class small molecules to induce remyelination and restore function in patients with Multiple Sclerosis (MS) and other demyelinating diseases.
• Expansion Plans: Funding will support advancing the MS program through human proof of concept studies and expanding the pipeline to address additional degenerative diseases.

Progentos Therapeutics' Target Market

• Target Market: Patients suffering from Multiple Sclerosis (MS) and other demyelinating diseases.
• Neurologists and Healthcare Providers: Medical professionals specializing in the treatment of MS and related conditions.
• Research Institutions and Clinical Trials: Collaborations with research institutions and participation in clinical trials to further validate the efficacy of their regenerative therapies.

What Progentos Therapeutics Needs to Buy

• Research and Development Partnerships: Collaborations with biotech and pharmaceutical companies for further research and development of regenerative therapies.
• Clinical Trial Support: Partnerships with contract research organizations (CROs) and clinical trial service providers for conducting human proof of concept studies.
• Manufacturing and Supply Chain Solutions: Establishing partnerships with manufacturers and suppliers for the production and distribution of their small molecules.